DB05924ExperimentalSmall molecule
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid... NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.
- Primary indication
- Investigated for use/treatment in parkinson's disease.Curator reviewed
- Code names
- NLX-P101
Which companies are running trials of NLX-P101, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account